Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals (Q83929696)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Viktor Dombrovskiy

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Andrew Martin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Harold Paz

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Health-System Pharmacy

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1151-1156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

The epidemiology of sepsis in the United States from 1979 through 2000

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

From the Food and Drug Administration

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Efficacy and safety of recombinant human activated protein C for severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Applying patient selection criteria for drotrecogin alfa therapy in practice.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Why immunomodulatory therapies have not worked in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

New and emerging therapies for sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Assessing the use of activated protein C in the treatment of severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

An economic evaluation of activated protein C treatment for severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Economic evaluation of new therapies in critical illness

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Risk-benefit analysis for drotrecogin alfa (activated).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Medicare to partly cover extra cost of sepsis therapy, drug-eluting stents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Drotrecogin alpha (activated).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

Managing high-cost biotechnology products.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050368

31 March 2020

Identifiers

DOI

10.2146/AJHP050368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16754741%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference